Open AccessCLINICAL SIGNIFICANCE OF SLC22A1 RS622342 GENETIC POLYMORPHISMIN TYPE 2 DIABETES MELLITUS PATIENTS, TAKING METFORMIN
Author(s) -
Vitaly Baranov,
Vitaly Baranov,
Н В Ворохобина,
Н В Ворохобина,
М Абулула,
М Абулула,
Ksenia Zagorodnikova,
Ksenia Zagorodnikova,
А. А. Топанова,
А А Топанова
Publication year - 2015
Publication title -
vestnik severo-zapadnogo gosudarstvennogo medicinskogo universiteta im. i.i. mečnikova
Language(s) - English
Resource type - Journals
eISSN - 2618-9704
pISSN - 2618-7116
DOI - 10.17816/mechnikov20157122-27
Subject(s) - metformin , medicine , genotype , type 2 diabetes , glycemic , type 2 diabetes mellitus , endocrinology , odds ratio , diabetes mellitus , polymorphism (computer science) , body mass index , allele , gene , genetics , biology
One of the key proteins that determine the pharmacokinetics of metformin is OCT1. rs622342 polymorphism in the gene SLC22A1 (OCT1) can reduce the expression of this protein. The aim of this study was to evaluate clinical significance of rs622342 in people with diabetes mellitus (DM) type 2, taking metformin. In 94 patients dynamics of the main indicators of glycemic control and body mass index were sudied over 6 months of treatment. At the end of the study 33 of 49 patients (67,3%) with wild-type variant of rs622342 (genotype AA) and 17 of 45 (37,7%) with polymorphic variants of the gene SLC22A1 (AC- and CC-genotypes) were taken metformin only and had HbA1c levels less than 7,0%. Remaining patients required a second hypoglycemic agent or had HbA1c levels 7,0% or more. Calculating odds ratios showed that the presence of AC- or CC- genotypes of rs622342 in the gene SLC22A1 increases the risk of poor clinical effect of metformin 3,4-fold (p = 0,004). Conclusion: The presence of a polymorphic allele C ( rs622342 ) in the gene SLC22A1 in patients with type 2 diabetes is associated with poor clinical effect of metformin monotherapy.